MDT vs ABT
MDT and ABT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | MDTMedtronic plc | ABTABBOTT LABORATORIES |
|---|---|---|
| Market cap | $112.73B | $189.61B |
| P/E (TTM) | 23.6 | 30.5 |
| P/B | 2.28 | 3.64 |
| P/S | 3.1x | 4.2x |
| Dividend yield | 3.23% | 2.17% |
| Revenue | $36.36B(TTM) | $45.13B(TTM) |
| Revenue growth (YoY) | 8.4% | 5.7% |
| Net income | $4.80B(TTM) | $6.28B(TTM) |
| Earnings growth (YoY) | 3.0% | -51.3% |
| EPS, diluted | $3.73(TTM) | $3.57(TTM) |
| EBIT margin | 17.8% | 18.2% |
| ROE | 9.7% | 12.5% |
| ROIC | 7.1% | 8.3% |
| Piotroski F | 8/9 | — |
| 1y total return | -3.0% | -14.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: MDT vs ABT
| Metric | MDT | ABT |
|---|---|---|
| End value | $15.2K | $32.5K |
| Total return | +52.3% | +225.5% |
| CAGR | +4.2% | +12.1% |
| Volatility | 23.2% | 23.9% |
| Sharpe | 0.12 | 0.43 |
| Sortino | 0.17 | 0.62 |
| Max drawdown | -45.3% | -39.6% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)